RSV Vaccine Receives FDA Approval for Adults Under 50

Pfizer received FDA approval for Abrysvo, the first respiratory syncytial virus (RSV) vaccine, for adults under 50 at increased risk of lower respiratory tract disease on October 22, 2024. 

“Abrysvo was previously approved for use by those 60 years and older, as well as for pregnant individuals at between 32 weeks and 36 weeks of gestation,” reported the Wall Street Journal. 

This vaccine is designed to prevent lower respiratory tract disease in adults aged 18 to 59 at a heightened risk for RSV, marking the first of its kind for this age group. Pfizer's new RSV vaccine offers protection against a significant respiratory illness for a specific adult population.

The FDA approved the vaccine based on data from a clinical trial involving adults with chronic medical conditions at risk of RSV-associated disease. Pfizer plans to publish the study results in a peer-reviewed journal.

Reference
Hart C. Pfizer receives FDA approval for RSV vaccine. Wall Street Journal. Published October 22, 2024. Accessed October 23, 2024. https://www.wsj.com/health/healthcare/pfizer-receives-fda-approval-for-rsv-vaccine-d9f390e0?mod=health_lead_pos2